

Fabio CICERI

L'attività di trapianto di
cellule staminali
emopoietiche in Italia

STATI GENERALI



RETE NAZIONALE
TRAPIANTI

6.7.8 NOVEMBRE


ROMA

LA RETE ITALIANA TRAPIANTI CSE

	TP Accreditati	ACCREDITAMENTO		
		Autologo	Allogenico	URD
Pediatrici (n=10)	10	10	8	6
Adulti (n=61)	61	61	31	33
Mixed (n=15)	15	15	13	9
TOTALI	86	86	52	48

Attività TRAPIANTO


Trasplanti Autologhi (n=71.402)



Export date 11/03/2019

DA VITA NASCE VITA: PROMUOVERE LA DONAZIONE DI CELLULE STAMINALI EMOPOIETICHE IN ITALIA


Trapianti Autologhi- Indicazioni 2018



Export date 11/03/2019


DA VITA NASCE VITA: PROMUOVERE LA DONAZIONE DI CELLULE STAMINALI EMOPOIETICHE IN ITALIA

Trapianti Autologhi- sorgente di HSC




Export date 11/03/2019

Trapianti Autologhi- età




Export date 11/03/2019

Trapianti allogenici (n = 36.435)




Export date 11/03/2019


Trapianti allogenici- Indicazioni 2018



Trapianti allogenici – indicazioni nel tempo




Trapianti allogenici - donatori



Export date 11/03/2019

Years


Trapianti allogenici – sorgente HSC



Export date 11/03/2019

DA VITA NASCE VITA: PROMUOVERE LA DONAZIONE DI CELLULE STAMINALI EMPOIETICHE IN ITALIA


Trapianti allogenici – URD Sorgente HSC



Export date 11/03/2019


Trapianti allogenici

HLA Identici familiari e sorgente HSC




Export date 11/03/2019

Trapianti allogenici Haplo familiari e sorgente HSC




Export date 11/03/2019

Trapianti allogenici - età



Export date 11/03/2019

Trapianti allogenici - condizionamenti



Export date 11/03/2019

Impatto della compatibilità HLA studio Gitmo-IBMDR *PI: drssa A Picardi*

Inclusion Criteria

N = 1789

01.01.2012 - 31.12.2015

- ✓ Adults : 18 -70 years
- ✓ Malignant Haematologic Disease
- ✓ First Allogeneic HSCT
- ✓ Stem Cell Source: BM or PBSC
- ✓ Patient's High Resolution (HR) HLA Typing for HLA-A/B/C/DRB1/DQB1 loci, at the start of the donor's search process
- ✓ Data source: GITMO (PROMISE) – IBMDR and AIBT Registry

METHODS



Table 1. Patient and donor characteristics

	N= 1789
Patient age, years, median (range)	49 (18-70)
Diagnosis, n (%)	
Acute Leukemia	1005 (56%)
Myeloproliferative Disorders	322 (18%)
Lymphoproliferative Disorders	462 (26%)
Secondary origin disease, n (%)	190 (11%)
Disease status at HSCT, n (%)	
Early	848 (47%)
Intermediate	445 (25%)
Advanced	496 (28%)
HCT-CI score, median (range)	1 (0-7)
Karnofsky PS/	90% (20-100)
EBMT score, median (range)	4 (1-7)
Donor age, years, median (range)	29 (18-57)
Female donor/male recipient, n (%)	305 (17%)
N° of pregnancies for female donors, median (range)	0 (0-6)
ABO Mismatch (%)	
No	577 (32%)
Major	526 (30%)
Minor	377 (21%)


Table 4. Conditioning and GvHD prophylaxis details

	N= 1789
Type of conditioning, n (%)	
MAC	1279 (71%)
RIC	510 (29%)
Conditioning details	
MAC-BuCy	282 (% a tutti)
MAC/RIC-TBF	342/90
MAC/RIC-ThioCy based	101/153
MAC/RIC-BuFlu based	257/111
MAC/RIC TreoFlu based	46/51
MAC/RIC TBI based	164/22 (10%)
MAC/RIC- FluMel based	41/27
MAC /RIC ThioFlu – FluCy based	21/13
Other MAC/RIC regimen	25/43
Source of stem cells, n (%)	
PB	1462 (82%)
BM	327 (18%)
ATG-based GvHD prophylaxis, n (%)	1612 (90%)
GvHD prophylaxis details	
ATG-CSA+MTX +/- other drug	1449 (81%)
ATG-CSA± other drug	89 (5%)
ATG-Sirolimus+MMF	47 (3%)
Other ATG-based prophylaxis	32 (2%)
CSA or Tacrolimus+MTX	106 (6%)
PTCy + CSA or Tacrolimus + MMF	31 (2%)
Other prophylaxis	25 (1%)



Overall Survival




TRM according to HLA matching



acute GVHD







GRUPPO ITALIANO PER IL TRAPIANTO DI MIDOLLO OSSEO, CELLULE STAMINALI EMOPOIETICHE E TERAPIA CELLULARE

STATI GENERALI



RETE NAZIONALE
TRAPIANTI

DA VITA NASCE VITA: PROMUOVERE LA DONAZIONE DI CELLULE STAMINALI EMOPOIETICHE IN ITALIA